Clinical Trials
-
Principal Investigator:
Steven J. Lobritto, MDIn this research, we want to learn more about how to improve care for children who are listed for or who have received a liver transplant. The goal of this research is to look at how different hospitals treat these children and to look at their outcomes to help improve care, decrease complications, shorten length of hospital stay, reduce hospital re-admissions and to possibly lower mortality rates and decrease adverse events, such as organ rejection, infection, and bleeding. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
James Hinkley Garvin Jr, MDChildren and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical therapy in... -
Principal Investigator:
James Hinkley Garvin Jr, MDChildren and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical therapy in... -
Principal Investigator:
James Hinkley Garvin Jr, MDChildren and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical therapy in... -
Principal Investigator:
Nobuko Hijiya, MDThis study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union (EU) European Medicines Agency (EMA), or others. The purpose of this study is to learn about the safety and effectiveness of nivolumab and relatlimab in participants with recurrent/relapsed or... -
Principal Investigator:
Nobuko Hijiya, MDThis study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union (EU) European Medicines Agency (EMA), or others. The purpose of this study is to learn about the safety and effectiveness of nivolumab and relatlimab in participants with recurrent/relapsed or... -
Principal Investigator:
Nobuko Hijiya, MDThis study is for 1 to 21-year-olds whose hematologic cancer has relapsed to take medication called Tagraxofusp. Relapse means that cancer has come back after treatment. Tagraxofusp is a drug approved by the FDA (Food and Drug Administration) but is not approved to treat the cancers of people in this study. This study is being done to find out if Tagraxofusp can be safely given together with other chemotherapy drugs for cancer. About 54 children and young adults will participate in this study. -
Principal Investigator:
Steven J. Lobritto, MDTReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three-arm clinical trial of immunosuppressive therapy for children with acute liver failure. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. The study will determine if corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition, as compared to supportive care. Participants will be enrolled while they are hospitalized for acute liver failure, and will continue to be... -
Principal Investigator:
Steven J. Lobritto, MDTReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three-arm clinical trial of immunosuppressive therapy for children with acute liver failure. This is a double-blind study, so the study doctors and participants will not know to which arm the participants are assigned. The study will determine if corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition, as compared to supportive care. Participants will be enrolled while they are hospitalized for acute liver failure, and will continue to be... -
Principal Investigator:
Nobuko Hijiya, MDThis study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that is used to treat many types of cancer and can cause damage to the heart in some children and young adults. The study doctors want to find out how safe the new study drug called venetoclax is when given with three other chemotherapy drugs called...